Piper Sandler Downgrades Eagle Pharmaceuticals (EGRX) to Underweight, 'Struggling Even More With The Long-Term Outlook'
Tweet Send to a Friend
(Updated - August 10, 2023 5:13 AM EDT)
Piper Sandler analyst David Amsellem downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper Sandler analyst David Amsellem downgraded Eagle Pharmaceuticals (NASDAQ: EGRX) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
